Blocking HMGB1 with anti-HMGB1 monoclonal antibodies ameliorates pain behaviors in rodent models of neuropathic and bone cancer pain [13,14] while injection of recombinant HMGB1 elicits pain behaviors in rodents [10]. Here, HMGB1 is linked to bone neoplasm.